TRNN-ASn: A Mitochondrial Protein Regulating Gene Expression and Cellular Processes

Target Name: TRNN

NCBI ID: G4570

TRNN

Other Name(s): mitochondrially encoded tRNA-Asn (AAU/C) | MTTN | mitochondrially encoded tRNA asparagine | MT-TN | Mitochondrially encoded tRNA asparagine

TRNN-ASn: A Mitochondrial Protein Regulating Gene Expression and Cellular Processes

TRNN (mitochondrially encoded tRNA-Asn (AAU/C)) is a protein that plays a crucial role in the regulation of gene expression in the mitochondria. It is a key component of the mitochondrial complex, which is responsible for ensuring the proper translation of mRNAs into the cytoplasm. Mutations in the TRNN gene have been linked to a variety of diseases, including neurodegenerative disorders, cancer, and cardiovascular disease.

The TRNN gene is encoded by a non-coding RNA molecule called tRNA-Asn (AAU/C). This tRNA-Asn molecule is derived from the amino acids Asp, Asn, and Gly that are found in the standard tRNA molecule. However, Unlike typical tRNA molecules, TRNN-ASn contains a modified Asn residue that is modified with a thioredoxin base, AsH. This modification is known as thioredoxination, and it is a common feature of proteins that are involved in the regulation of gene expression.

Thioredoxination is a critical modification that allows TRNN-ASn to interact with a variety of molecules, including transcription factors, RNA-binding protein (RBP), and DNA-binding protein (DBP). These interactions play a crucial role in regulating the translation of mRNAs into the cytoplasm.

One of the key functions of TRNN-ASn is its role in the regulation of mitochondrial gene expression. It is well established that many diseases, including neurodegenerative disorders, are caused by mutations in genes that are expressed in the mitochondria. These mutations can disrupt the function of TRNN-ASn, leading to the misregulation of gene expression and the development of disease.

In addition to its role in the regulation of mitochondrial gene expression, TRNN-ASn is also involved in the regulation of cellular processes that are critical for the survival of cells. For example, TRNN-ASn has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die when they are no longer needed.

TRNN-ASn is also involved in the regulation of cellular signaling pathways that are critical for the growth and survival of cells. For example, TRNN-ASn has been shown to play a role in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cellular signaling pathways that are critical for cell growth and survival.

Due to its involvement in the regulation of mitochondrial gene expression and cellular processes, TRNN-ASn is a potential drug target or biomarker for a variety of diseases. For example, TRNN-ASn has been shown to be involved in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Additionally, TRNN-ASn has been shown to be involved in the regulation of cancer cell growth and survival, which makes it a potential target for cancer therapies.

In conclusion, TRNN-ASn is a protein that plays a crucial role in the regulation of gene expression in the mitochondria. Its modified Asn residue, which is modified with a thioredoxin base, AsH, allows it to interact with a variety of molecules that are involved in the regulation of gene expression and cellular processes. TRNN-ASn is a potential drug target or biomarker for a variety of diseases, including neurodegenerative disorders, cancer, and cardiovascular disease. Further research is needed to fully understand the role of TRNN-ASn in the regulation of gene expression and cellular processes, and to develop effective therapies based on this understanding.

Protein Name: Mitochondrially Encoded TRNA Asparagine

The "TRNN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRNN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets